BioMed X launches call for applications in autoimmune disease research
The project will explore the biology of human autoreactive plasma cells
Read More
Tag: Servier
European Commission green lights Servier’s Tibsovo
Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma
Read More
Victory Road: NHS successful in 11 year claim against Servier
The European Commission finds that Servier committed a breach of competition over blood pressure drug
Read More
Servier and MiNA Therapeutics ink neurology pact
Companies will develop saRNA therapies to treat neurological diseases
Read More
Servier acquires Pixuvri from CTI BioPharma
The treatment was approved for use in the European Union in June this year.
Read More
Pixuvri approved for use in EU
The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.
Read More
Shire completes sale of oncology franchise to Servier
Shire has completed the sale of its oncology franchise to Servier in a deal valued at $2.4 billion.
Read More
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read More
Shire sells oncology unit to Servier for $2.4bn
Dublin, Ireland-based Shire is selling its oncology unit to France’s Servier in a deal worth $2.4 billion.
Read More
Servier’s Lonsurf backed for NHS use
Patients with advanced bowel cancer in England and Wales stand to gain routine access to a new treatment option after cost regulators backed NHS funding for Servier’s Lonsurf.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
